Dr Reddy's launches generic Sevelamer carbonate tablets in US

Dr Reddy's Laboratories has said it has launched in the American market generic Sevelamer carbonate tablets used for controlling serum phosphorus in people with chronic kidney disease on dialysis.
The company has launched the tablets in the strength of 800 mg after the approval of the United States Food and Drug Administration (USFDA), Dr Reddy's said in a statement.
The company's product is generic version of Genzyme Corporation's Renvela tablets, it added.
"This launch represents Dr Reddy's expertise and commitment to providing affordable alternatives for complex, limited-competition products to market," Dr Reddy's Executive VP and Head of the North America Generics business Alok Sonig said.

This is the company's eighth overall and fourth limited- competition launch this fiscal year, Dr Reddy's said.
"The Renvela brand and generic had US sales of approximately USD 1.88 billion MAT for the most recent twelve months ended July 2017 according to IMS Health,"it added.
Renvela is indicated for the control of serum phosphorus in adults and children six years of age and above with chronic kidney disease on dialysis.